ALX1-11 recombinant human parathyroid hormone data

AXB (Toronto) announced that two Phase I trials in the Netherlands found the treatment was safe and well-tolerated, and did not produce hypercalcemia after single or repeated dosing subcutaneously in 72 healthy, post-menopausal volunteers.

Measures of serum calcium and other markers of bone formation and resorption showed no risk of hypercalcemia at the doses of 0.5, 1, 2, 3, and 5 µg/kg administered in a single dose or daily for seven days. ...